Development of the Inactivated QazCovid-in Vaccine: Protective Efficacy of the Vaccine in Syrian Hamsters.
QazCovid-in
SARS-CoV-2
Syrian hamsters
inactivated vaccine
protective efficacy
Journal
Frontiers in microbiology
ISSN: 1664-302X
Titre abrégé: Front Microbiol
Pays: Switzerland
ID NLM: 101548977
Informations de publication
Date de publication:
2021
2021
Historique:
received:
04
06
2021
accepted:
30
08
2021
entrez:
14
10
2021
pubmed:
15
10
2021
medline:
15
10
2021
Statut:
epublish
Résumé
In March 2020, the first cases of the human coronavirus disease COVID-19 were registered in Kazakhstan. We isolated the SARS-CoV-2 virus from clinical materials from some of these patients. Subsequently, a whole virion inactivated candidate vaccine, QazCovid-in, was developed based on this virus. To develop the vaccine, a virus grown in Vero cell culture was used, which was inactivated with formaldehyde, purified, concentrated, sterilized by filtration, and then adsorbed on aluminum hydroxide gel particles. The formula virus and adjuvant in buffer saline solution were used as the vaccine. The safety and protective effectiveness of the developed vaccine were studied in Syrian hamsters. The results of the studies showed the absolute safety of the candidate vaccine in the Syrian hamsters. When studying the protective effectiveness, the developed vaccine with an immunizing dose of 5 μg/dose specific antigen protected animals from a wild homologous virus at a dose of 10
Identifiants
pubmed: 34646246
doi: 10.3389/fmicb.2021.720437
pmc: PMC8503606
doi:
Types de publication
Journal Article
Langues
eng
Pagination
720437Informations de copyright
Copyright © 2021 Zhugunissov, Zakarya, Khairullin, Orynbayev, Abduraimov, Kassenov, Sultankulova, Kerimbayev, Nurabayev, Myrzakhmetova, Nakhanov, Nurpeisova, Chervyakova, Assanzhanova, Burashev, Mambetaliyev, Azanbekova, Kopeyev, Kozhabergenov, Issabek, Tuyskanova and Kutumbetov.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Microbiol Mol Biol Rev. 2005 Dec;69(4):635-64
pubmed: 16339739
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
iScience. 2021 Feb 19;24(2):102054
pubmed: 33521604
Viral Immunol. 2010 Oct;23(5):509-19
pubmed: 20883165
J Gen Virol. 2010 Jun;91(Pt 6):1450-60
pubmed: 20147516
PLoS One. 2020 Feb 26;15(2):e0229279
pubmed: 32101582
ACS Infect Dis. 2016 May 13;2(5):361-76
pubmed: 27627203
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Vaccines (Basel). 2021 Mar 03;9(3):
pubmed: 33802467
Hong Kong Med J. 2016 Jun;22(3 Suppl 4):25-31
pubmed: 27390007
Cell. 2021 Apr 29;184(9):2372-2383.e9
pubmed: 33743213
J Biomed Sci. 2020 Dec 20;27(1):104
pubmed: 33341119
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
Virus Res. 2008 Apr;133(1):20-32
pubmed: 17499378
Virol Sin. 2021 Apr 9;:
pubmed: 33835391
Virol J. 2015 Dec 22;12:209
pubmed: 26690088
J Med Virol. 2020 Apr;92(4):401-402
pubmed: 31950516
Science. 2020 Jul 3;369(6499):77-81
pubmed: 32376603
JCI Insight. 2019 Feb 21;4(4):
pubmed: 30830861
Clin Infect Dis. 2020 Dec 3;71(9):2428-2446
pubmed: 32215622
J Virol. 2011 Dec;85(23):12201-15
pubmed: 21937658
Bull World Health Organ. 1983;61(4):689-92
pubmed: 6605215
Expert Rev Vaccines. 2012 Jun;11(6):695-719
pubmed: 22873127
Virol J. 2014 May 06;11:82
pubmed: 24885320
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
EClinicalMedicine. 2021 Sep;39:101078
pubmed: 34414368
Sci Rep. 2021 Mar 11;11(1):5804
pubmed: 33707532
Vaccine. 1989 Dec;7(6):513-20
pubmed: 2481909
J Infect Dis. 2014 Nov 1;210 Suppl 1:S439-46
pubmed: 24634499
Int J Biol Sci. 2020 Mar 15;16(10):1686-1697
pubmed: 32226286
Nature. 2020 Jul;583(7818):834-838
pubmed: 32408338
Hong Kong Med J. 2012 Feb;18 Suppl 2:31-6
pubmed: 22311359
Lancet. 2021 Feb 20;397(10275):671-681
pubmed: 33545094
Proc Natl Acad Sci U S A. 2020 Jul 14;117(28):16587-16595
pubmed: 32571934
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
J Thorac Dis. 2013 Aug;5 Suppl 2:S103-8
pubmed: 23977429
Nat Rev Immunol. 2005 Dec;5(12):917-27
pubmed: 16322745
Trends Microbiol. 2016 Jun;24(6):490-502
pubmed: 27012512
Vaccine. 2007 Oct 10;25(41):7041-6
pubmed: 17825459
Microbiol Aust. 2020 Mar 17;:MA20013
pubmed: 32226946
Nature. 2020 Oct;586(7830):516-527
pubmed: 32967006
PLoS One. 2012;7(4):e35421
pubmed: 22536382
Hum Vaccin Immunother. 2016 Sep;12(9):2351-6
pubmed: 27269431
Vaccine. 2011 Feb 17;29(9):1844-9
pubmed: 21195802
J Biol Chem. 2004 Feb 20;279(8):6235-43
pubmed: 14638685
J Immunol. 1984 Feb;132(2):920-7
pubmed: 6197478
Diseases. 2016 Jul 25;4(3):
pubmed: 28933406
J Virol. 2005 Jan;79(1):503-11
pubmed: 15596843
Signal Transduct Target Ther. 2020 Oct 13;5(1):237
pubmed: 33051445
Lancet. 2020 Nov 14;396(10262):1595-1606
pubmed: 33065034
N Engl J Med. 2021 Jun 17;384(24):2354-2356
pubmed: 33822491
J Virol. 2020 Feb 14;94(5):
pubmed: 31826992
J Virol. 2014 Oct;88(20):11955-64
pubmed: 25100844